Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 10Phase 1/2 5Phase 1 2

Status

Completed 8Recruiting 5Terminated 4Withdrawn 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 3Sarcoma 1Neoplasm Metastasis 1Melanoma 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × eribulin × Clear all
NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Hoosier Cancer Research Network

Phase 1/2 Recruiting
41 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
154 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡